Headline News

 

Johnson & Johnson to present new neuropsychiatry data across 24 studies at Psych Congress 2026

Posted on September 09, 2026

Johnson & Johnson highlights broad multiple myeloma pipeline with more than 35 studies at IMS 2026

Posted on September 09, 2026

Takeda’s oveporexton delivers broad symptom improvements in Phase 3 narcolepsy type 1 studies

Posted on September 09, 2026

BrainChild Bio raises $116 million in Series A funding

Posted on September 08, 2026

BrainChild Bio launches pivotal trial of CAR T therapy for aggressive pediatric brain cancer

Posted on September 08, 2026

Gan & Lee licenses obesity drug bofanglutide to Menarini for European markets

Posted on September 08, 2026

Bayer moves into blockbuster launch phase as seed and crop protection pipeline advances

Posted on September 08, 2026

Abbott’s TactiFlex Duo shows strong 12 month outcomes in paroxysmal atrial fibrillation study

Posted on September 08, 2026

BeOne Medicines strikes voluntary deal with US government to widen access to its cancer drugs

Posted on September 08, 2026

Bristol Myers Squibb reports positive early results for GPRC5D-targeted CAR T therapy in multiple myeloma

Posted on September 08, 2026

Novartis remibrutinib significantly reduces relapse rates in Phase III relapsing multiple sclerosis studies

Posted on September 08, 2026

Lilly agrees to buy Merida Biosciences, betting on antibody-targeting approach to autoimmune disease

Posted on September 08, 2026

New year-long data show Taltz and Zepbound combination sustains gains in psoriatic disease and obesity

Posted on September 08, 2026

Sanofi’s MenQuadfi cleared in the EU for infants from six weeks old against invasive meningococcal disease

Posted on September 08, 2026

Novartis del desiran misses primary endpoint in Phase III HARBOR trial for myotonic dystrophy type 1

Posted on September 08, 2026